Given that CBP/p300 play important roles in maintaining MLL-r leukemia, this suggests that chemical inhibition of CBP or p300 may present a therapeutic strategy for treating MLL-r AMLs (Roe et al., 2015). The gene discussed is EP300; the disease is leukemia.